Memic Hominis System
Israeli medtech startup Memic Innovative Surgery, a medical device company which develops new technology for robot-assisted surgery, is planning an initial public offering. The IPO is expected to be held through an SPAC merger and according to Globes the company expects to come away with a $1 billion valuation.
Investopedia explains that a special purpose acquisition company (SPAC) is a company with no commercial operations that is formed strictly to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. Also known as “blank check companies,” SPACs have been around for decades. In recent years, they’ve become more popular, attracting big-name underwriters and investors and raising a record amount of IPO money in 2019.
Just last month the company closed a $96 million Series D round of financing. The financing round was led by Peregrine Ventures and Ceros with participation from OurCrowd and Accelmed.
–
Memic declares that its mission is to transform robot-assisted surgery. Its main product is Memic’s Hominis surgical platform which features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation for various access configurations. The company states that this makes it ideal for minimally-invasive procedures that until now have been off-limits to robot-assisted surgery.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Hominis is the only FDA authorized product for transvaginal robotic surgery.
Dvir Cohen, co-founder and CEO of Memic, said “The Hominis system represents a significant advancement in the growing multi-billion-dollar robotic surgery market. This financing positions us to accelerate our commercialization efforts and bring Hominis to both surgeons and patients in the months ahead.”
–
Read this @SFBJNews article to learn more about how we raised $96M in a series D financing to support our commercialization and geographical expansion to our new U.S. office. We are excited to continue grow and build our worldwide commercial capabilities! https://t.co/23koHqchr1
— Memic Innovative Surgery (@memicmed) May 20, 2021
The Hominis system received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. It is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles.
